1. Home
  2. BIRK vs BLTE Comparison

BIRK vs BLTE Comparison

Compare BIRK & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

N/A

Current Price

$30.01

Market Cap

5.6B

Sector

N/A

ML Signal

N/A

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$169.44

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BIRK
BLTE
Founded
1774
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.0B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
BIRK
BLTE
Price
$30.01
$169.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
7
Target Price
$61.43
$198.00
AVG Volume (30 Days)
2.4M
182.2K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.71
N/A
Revenue Next Year
$14.30
$492.11
P/E Ratio
$17.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.25
$65.00
52 Week High
$50.73
$200.00

Technical Indicators

Market Signals
Indicator
BIRK
BLTE
Relative Strength Index (RSI) 28.97 54.32
Support Level N/A $167.80
Resistance Level $37.29 $182.61
Average True Range (ATR) 1.18 8.34
MACD -0.24 0.96
Stochastic Oscillator 6.08 47.17

Price Performance

Historical Comparison
BIRK
BLTE

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: